An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 68, Issue 9, 2009, Pages 1433-1439

  Denton, C P ^a   Engelhart, M ^b   Tvede, N ^b   Wilson, H ^a   Khan, K ^a   Shiwen, X ^a   Carreira, P E ^c   Diaz Gonzalez, F ^d   Black, C M ^a   Van Den Hoogen, F H ^e  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d University Hospital   (Spain)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COLLAGEN TYPE 1; DRUG ANTIBODY; INFLIXIMAB; N TERMINAL COLLAGEN TYPE 3 PROPEPTIDE; PEPTIDE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FINGER ISCHEMIA; FUNCTIONAL ASSESSMENT; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION; ISCHEMIA; KIDNEY DISEASE; MALE; MYALGIA; NECK PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; QUESTIONNAIRE; RAYNAUD PHENOMENON; RIGOR; SELF REPORT; SKIN BIOPSY; SYSTEMIC SCLEROSIS; TREATMENT DURATION; ULCER; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BIOPSY; CELLS, CULTURED; COLLAGEN TYPE I; DERMATOLOGIC AGENTS; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69949138488     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.096123     Document Type: Article

References (39)

1. Denton CP, Black CM. Targeted therapy comes of age in scleroderma. Trends Immunol 2005;26:596-602. (Pubitemid 41726447)
2. Nihtyanova SI, Denton CP. Current approaches to the management of early active diffuse scleroderma skin disease. Rheum Dis Clin North Am 2008;34:161-79; viii.
3. Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN. Anti-TNF therapy: where have we got to in 2005? J Autoimmun 2005;25(Suppl):26-28 (Pubitemid 41728040)
4. Kleyn CE, Griffiths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther 2006;6:797-805.
5. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005;65:2253-2286 (Pubitemid 41571985)
6. Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999;14:47-51. (Pubitemid 29295303)
7. Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:330-338 (Pubitemid 43845410)
8. Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995;63:48-56.
9. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-15225 (Pubitemid 30337246)
10. Inagaki Y, Truter S, Tanaka S, Di Liberto M, Ramirez F. Overlapping pathways mediate the opposing actions of tumor necrosis factor-alpha and transforming growth factor-beta on alpha 2(I) collagen gene transcription. J Biol Chem 1995;270:3353-3358
11. Gao Q, Meijer MJ, Schluter UG, van Hogezand RA, van der Zon JM, van den Berg M, et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 2007;13:693-702. (Pubitemid 46909983)
12. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, Dayer JM. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003;48:2593-2604 (Pubitemid 37129436)
13. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004;50:1040-1050
14. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534 (Pubitemid 26422549)
15. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003;28:604-607
16. Ellman MH, McDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: a pilot study [abstract]. Arthritis Rheum 2000;43(Suppl):s392.
17. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34:1636-1637 (Pubitemid 47068007)
18. Pope JE, Bellamy N. Outcome measurements in scleroderma clinical trials. Semin Arthritis Rheum 1993;23:22-33. (Pubitemid 23270891)
19. Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial - lessons learned. Semin Arthritis Rheum 2004;33:249-263 (Pubitemid 38280824)
20. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990;33:1256-1263
21. Medsger TA, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-2167 (Pubitemid 29487010)
22. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-1991
23. Serednicka K, Brough G, Black C, Denton CP. Utility of a self-reported functional score in assessing disease progression in systemic sclerosis. Rheumatology 2007;46:1107-1110 (Pubitemid 47050612)
24. McHugh NJ, Distler O, Giacomelli R, Riemekasten G. Non organ-based laboratory markers in systemic sclerosis. Clin Exp Rheumatol 2003;21:S32-8. (Pubitemid 41116909)
25. Nagy Z, Czirjak L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005;23:165-172 (Pubitemid 40662995)
26. Steen VD, Engel EE, Charley MR, Medsger TA Jr. Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol 1996;23:646-649 (Pubitemid 26132849)
27. Scheja A, Akesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA, Vischer UM. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001;3:178-182 (Pubitemid 32303434)
28. Chen Y, Shi-wen X, Eastwood M, Black CM, Denton CP, Leask A, Abraham DJ. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006;54:1309-1316 (Pubitemid 43672944)
29. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-36 (Pubitemid 43054276)
30. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma [abstract]. Arthritis Rheum 2006;55(Suppl):S243.
31. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti-TGFb1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-333 (Pubitemid 46106206)
32. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-553 (Pubitemid 38834038)
33. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al, ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549
34. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-715
35. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994;37:278-288
36. Dziadzio M, Smith R, Abraham DJ, Stratton RJ, Gabrielli A, Black CM, Denton CP. Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. Clin Exp Rheumatol 2004;22:356-367 (Pubitemid 38585242)
37. Scheja A, Akesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA, Vischer UM. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001;3:178-182 (Pubitemid 32303434)
38. Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, Denton CP. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007;56:2422-2431 (Pubitemid 47173590)
39. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al. EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-981